T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) remains one of the most challenging hematological malignancies. Despite progress in therapeutics, majority of patients succumb to this neoplasm. CD33 is a proven therapeutic target, given its expression on most AML cells. Almost all anti-CD33 antibodies targe...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Main Authors: Hoseini, Sayed Shahabuddin, Vadlamudi, Mallika, Espinosa-Cotton, Madelyn, Tran, Hoa, Feng, Yi, Guo, Hong-fen, Xu, Hong, Cheung, Irene, Cheung, Nai-Kong V
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2021
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8154967/
https://ncbi.nlm.nih.gov/pubmed/34035113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002509
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares